A. Arida, P. Sfikakis
First Department of Propedeutic Internal Medicine Laikon Hospital, Athens University Medical School, Athens, Greece. email@example.com
2014 Vol.32, N°4 ,Suppl.84 - PI 0149, PF 0155
Free to view (click on article PDF icon to read the article)
Unmet therapeutic needs in Behçet`s disease have drawn recent attention to biological agents targeting cytokines other than TNF. The anti-IL-17 antibody secukinumab and the anti-IL-2 receptor antibody daclizumab were not superior to placebo for ocular Behçet`s in randomised controlled trials, comprising 118 and 17 patients, respectively. The anti-IL-1 agents anakinra and canakinumab and the anti-IL-6 agent tocilizumab were given to isolated refractory disease patients, who were either anti-TNF naïve (n=9) or experienced (n=18). No new safety signals were reported. Although a potential for bias to report positive effects and underreport negative cases may exist, Anakinra was partially effective, whereas disease remission was noted after canakinumab in some anti-TNF resistant patients. Tocilizumab appeared effective for neuro-Behçet`s, but not for mucocutaneous manifestations. Finally, in a pilot study of 7 patients with relapsing posterior uveitis refractory to azathioprine and/or cyclosporine, the anti-IL-1β antibody Gevokizumab was beneficial. Collectively, it seems that IL-1 and IL-6 are promising targets in patients refractory or intolerant to other regimens including anti-TNFs. However, controlled studies are surely needed.
PMID: 25268669 [PubMed]
Received: 05/06/2014 - Accepted : 17/09/2014 - In Press: 30/09/2014 - Published: 30/09/2014